Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Cash & Equivalents (2016 - 2025)

Dexcom (DXCM) has disclosed Cash & Equivalents for 15 consecutive years, with $134.2 million as the latest value for Q4 2024.

  • On a quarterly basis, Cash & Equivalents fell 76.3% to $134.2 million in Q4 2024 year-over-year; TTM through Dec 2024 was $134.2 million, a 76.3% decrease, with the full-year FY2024 number at $134.2 million, down 76.3% from a year prior.
  • Cash & Equivalents was $134.2 million for Q4 2024 at Dexcom, down from $621.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $1.4 billion in Q3 2021 to a low of $134.2 million in Q4 2024.
  • A 5-year average of $768.0 million and a median of $707.0 million in 2022 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 118.64% in 2021, then crashed 76.3% in 2024.
  • Dexcom's Cash & Equivalents stood at $817.6 million in 2020, then increased by 28.74% to $1.1 billion in 2021, then plummeted by 38.98% to $642.3 million in 2022, then dropped by 11.83% to $566.3 million in 2023, then plummeted by 76.3% to $134.2 million in 2024.
  • Per Business Quant, the three most recent readings for DXCM's Cash & Equivalents are $134.2 million (Q4 2024), $621.2 million (Q3 2024), and $939.2 million (Q2 2024).